A synthetic peptide acting as a triple agonist for GLP-1, GIP, and glucagon receptors, designed for treating obesity and type 2 diabetes by promoting weight loss and glycemic control.
The paper reviews a new drug called retatrutide that activates three hormone receptors (GLP‑1, GIP, and glucagon). Early human studies show it may improve blood sugar control, promote weight loss, boost energy use, and help liver fat, with a decent safety profile. While it’s not yet on the market, the data suggest it could become a powerful tool for tackling obesity, diabetes, and related metabolic issues.
Gut hormones like GLP‑1, GIP, and glucagon control hunger and can affect metabolism beyond just eating. A new drug called retatrutide, which activates all three hormone receptors at once, has been shown in recent human studies to help people lose weight and improve metabolic health. However, the exact dosing, long‑term safety, and how diet, exercise, and sleep interact with these hormones still need more research.
Retatrutide is a new drug that hits three hormone receptors (GLP‑1, GIP, and glucagon) and was tested in a small early‑stage trial with people who have type‑2 diabetes. It appeared safe, can be taken once a week, and lowered blood sugar and body weight a bit more than the older GLP‑1 drug dulaglutide, though it hasn’t yet been compared to the more powerful drugs semaglutide or tirzepatide. Bigger, longer studies are still needed to confirm how well it works and how safe it is.
A new wave of drugs that hit both the glucagon and GLP‑1 receptors—like retatrutide—are showing big weight‑loss results in early trials, often better than current meds. They may also help with diabetes and heart risk, but they’re still experimental and not yet on the market. The review flags that cost, access, and long‑term safety will be key issues as they move toward approval.
The article reviews how new obesity drugs like retatrutide can cause big weight drops (up to 24%) and might also protect the heart, beyond just slimming you down. It explains why older weight‑loss methods often fail to keep the weight off or improve heart health, and why these newer drugs are exciting for people looking to boost longevity and metabolic health.
GLP‑1 drugs (like semaglutide) and the newer triple‑agonist retatrutide not only help control blood sugar and curb appetite, they also appear to protect brain cells, lower inflammation, and may influence addiction‑related pathways. Early reports suggest they could help with depression, anxiety, dementia, and substance‑use issues, but the main side‑effects are stomach‑related and rare serious risks.
Bhat. Sowrabha S; Fernandez. Cornelius J CJ; Lakshmi. Vijaya V; Pappachan. Joseph M JM
The abstract reviews the newest wave of drugs that hit multiple gut hormones at once – GLP‑1, GIP and glucagon – and highlights that these “incretin co‑agonists” can cause big drops in weight, improve blood sugar, lipids and liver fat, and may lower heart‑related events. It points out that the newest triple‑agonist, retatrutide, is among the most powerful for weight loss, but the piece is a broad overview rather than a detailed trial report.
Hudanich. Mia M; Smith. Shannon N SN; Marino. Amanda A; Riskin. Suzanne I SI
The review shows that GLP‑1 drugs (like semaglutide) help women with PCOS lose weight and become more insulin‑sensitive, and that newer combo drugs that also hit the GIP receptor (tirzepatide) or hit GLP‑1, GIP, and glucagon (retatrutide) may work even better. Some studies even reported improvements in menstrual pain and ovarian appearance. The data are still early and the triple‑agonist isn’t FDA‑approved yet, but the trend points to stronger metabolic and hormonal benefits from the newer agents.
Gaffey. Robert H RH; Takyi. Afua K AK; Shukla. Alpana A
The review explains that gut hormones GLP‑1 and GIP can both help people lose weight, but the way they work is still being figured out. Surprisingly, drugs that either turn on (agonists) or block (antagonists) the GIP receptor can both cause weight loss, likely because engineered peptides trigger different cellular signals than the natural hormone. New compounds that mix GLP‑1 and GIP activity, like the experimental drug retatrutide, look promising for stronger weight‑loss effects, but more research is needed before they can be used safely outside clinical trials.
Giblin. Kathryn K; Kaplan. Lee M LM; Somers. Virend K VK; Le Roux. Carel W CW; Hunter. David J DJ; W...
Retatrutide is a new drug that hits three gut hormone receptors (GIP, GLP‑1, and glucagon) and is being tested in huge Phase 3 trials called TRIUMPH. The studies will see if weekly injections can help people lose weight and also improve sleep‑apnea severity and knee‑joint pain in obese adults. No results are out yet—just the plan for the trials.
Himmerich. Hubertus H; Bentley. Jessica J; McElroy. Susan L SL
The review says binge‑eating disorder often comes with ADHD, mood issues, substance use and obesity. It recommends lisdexamfetamine and topiramate for binge eating, and lists other meds for the common co‑conditions. New drugs like tirzepatide and retatrutide (combo GLP‑1, GIP, glucagon agonists) might cut binge episodes, but there’s no solid proof yet.
Neumann. Joachim J; Ahlrep. Undine U; Hofmann. Britt B; Gergs. Ulrich U
In mouse heart tissue, the drug retatrutide (a triple‑receptor agonist) didn't make the heart muscle contract harder, but it did speed up the heart's beating rate by activating the glucagon receptor and raising cAMP inside the cells. This heart‑rate‑raising effect works differently from classic beta‑adrenergic stimulants like isoprenaline and can be blocked by certain other drugs.
Heerspink. Hiddo J L HJL; van Raalte. Daniël H DH; Bjornstad. Petter P; Bunck. Mathijs C MC; Wu...
The TRANSCEND-CKD study is a Phase 2b trial testing weekly retatrutide (a triple‑receptor agonist) in overweight adults with chronic kidney disease, some of whom also have type‑2 diabetes. The trial will see if the drug can improve kidney filtration rates over 24 weeks, but no results are reported yet—only how the study is set up and who is in it.
Nicze. Michał M; Dec. Adrianna A; Borówka. Maciej M; Krzyżak. Damian D; Bołdy...
The paper explains that obesity comes from taking in more calories than you burn and points to several body systems that control appetite and metabolism. It highlights that drugs mimicking gut hormones—especially GLP‑1 drugs like liraglutide and semaglutide, and the newer dual GLP‑1/GIP drug tirzepatide—can cause big weight loss and improve blood sugar. It also notes that new experimental molecules are being tested for future obesity treatments.
Cui. Xin X; Zhu. Yueming Y; Zeng. Lidan L; Zhang. Mengyuan M; Uddin. Amad A; Gillespie. Theresa W TW...
In mouse studies, the weight‑loss drug retatrutide lowered a sugar‑making pathway in fat cells, which stopped a cancer‑promoting protein (YAP) from being stabilized. This led to smaller tumors and made chemotherapy work better in obese mice with triple‑negative breast cancer. The work is still early and done only in animals.
Mainieri. Francesca F; La Bella. Saverio S; Rinaldi. Marta M; Chiarelli. Francesco F
The paper talks about rare genetic forms of obesity in kids, saying that DNA testing can spot them early and that a few drugs (setmelanotide, metreleptin) already work for some types. It also mentions newer drugs like liraglutide, semaglutide and retatrutide as promising, but there’s still no solid data or dosing advice for children.
Cigrovski Berkovic. Maja M; Ruzic. Lana L; Cigrovski. Vjekoslav V; Strollo. Felice F
GLP‑1 based weight‑loss drugs like semaglutide, tirzepatide and retatrutide can help you lose 5‑10% of body weight, but they also tend to shave off some muscle along with fat. Losing muscle may make it harder to keep the weight off and could lead to sarcopenia, so future treatments should aim to protect or even build muscle while you burn fat.
Researchers created a new 21‑question survey (EBAQ) to better capture how people with obesity feel hungry and what they eat, especially when they’re on a drug like retatrutide. The survey was tested with patients and doctors and was found clear and useful.
The article is a broad review of obesity drugs being used or soon to be used in India. It talks about how newer medicines can help people lose weight, but most of the information comes from clinical trials, not everyday use, and cost and safety in real life are still big questions.
Alsaqaaby. Moath S MS; Cooney. Sarah S; le Roux. Carel W CW; Pournaras. Dimitri J DJ
The review looked at who was actually enrolled in obesity drug trials over the last 30 years. It found that most studies mostly included White, middle‑aged women with moderate obesity, while men, people of color, older adults, and those with very high BMI were left out. This means the published results may not fully apply to those missing groups.